Recent research indicates that lenalidomide and pomalidomide may reduce CCR5 expression levels in peripheral blood mononuclear cells (PBMCs), consequently combating MM cells and ameliorating disease progression [12]. Here, CCR5 is linked to Miyoshi myopathy.